News
-
-
-
-
-
-
-
PRESS RELEASE
TAKKT AG: Final quarter of 2023 in line with expectations - focus on gross profit margin, cost management and cash pays off
TAKKT AG reports final quarter 2023 results in line with expectations, focusing on gross profit margin, cost management, and cash generation. Dividend proposal of EUR 1.00 per share. Earnings call on February 15, 2024 -
PRESS RELEASE
EQS-Adhoc: TAKKT AG: TAKKT Management Board proposes payment of a dividend of EUR 1.00 per share
TAKKT AG Management Board proposes a dividend of EUR 1.00 per share, subject to Supervisory Board approval. Proposal includes base dividend of EUR 0.60 and special dividend of EUR 0.40, in line with dividend policy -
PRESS RELEASE
TAKKT wins German Sustainability Award 2024
-
-
University of York Chooses Alces Flight to Boost Sustainable Research
-
Alset Capital Inc. Announces AI GPU Contract with a $91.7M Option Signed by Investee Company Cedarcross
-
Ivanhoe Electric Clarifies Certain Misleading Media Headlines Regarding Its Recent Registration Statement Filing
-
FE Battery Metals Announces Positive Laboratory Results Producing Lithium Carbonate Grades Exceeding 99% Purity
-
SouthGobi Announces Update on Mongolia Tax Audit
-
MGI – Media and Games Invest SE held its Annual General Meeting
-
Mililk® now available at Penny
-
TUI AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
-
German Software Company comforte AG Receives International Award: Excellence in Cybersecurity for Banks and Payment Service Providers
-
NET DIGITAL AG launches innovative AI product airis:ident for fully automated and legally compliant identity verification worldwide
-
Moody’s reaffirms « A1 » Outlook Stable rating of CNP Assurances SA
-
EURAZEO OPENS AN OFFICE IN TOKYO, FURTHER EXTENDING ITS INTERNATIONAL REACH
-
imerys-12-06-2024-implementation-of-the-share-buyback-program
-
COGELEC : Statement on the total number of shares and voting rights.
-
Biophytis announces the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens